Denmark Pharmaceutical Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 3.40 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Denmark Pharmaceutical Market Analysis
Denmark Pharmaceutical Market is poised to grow at a CAGR of 3.4% during the forecast period (2022-2027).
The majority of pharmaceutical and biotech companies are concentrating their research & development departments on finding new compounds or leads for the treatment of this disease, which is in the last stages of clinical trials, as a result of the COVID-19 pandemic. By providing funding and incentives to the pharmaceutical corporations, the local government further supports those clinical trials. The Danish Ministry of Health awarded 18.8 million Danish Kroner in November 2020 to test a novel coronavirus vaccine created by scientists at the nation's State Serum Institute (SSI). In order to guarantee that the vaccination is accessible to around 2 million individuals in Europe, Denmark also agreed to a fourth contract with BioNTech/Pfizer in November 2020. BioNTech/Pfizer is now thought to be a prospective vaccine manufacturer. Thus, in the long term, the market is expected to grow.
One of the foundational areas of the Danish economy is the pharmaceutical sector. Compared to other European nations, the nation boasts a sizable pharmaceutical and biotechnology sector, as well as a number of indigenous enterprises that conduct pharmaceutical product development and production. Pharmaceutical businesses have been making innovations including strategic mergers, collaborations, and investments in order to take advantage of the prospects that are currently present and in the future. In order to supplement its ongoing clinical activities in immuno-dermatology, UNION therapeutics A/S inked an agreement in July 2020 to purchase LEO Pharma A/global S's rights to the LEO PDE4 inhibitor chemical series. The substance was given the new name "UNI500" and is a class of PDE4 inhibitors. In June 2020, Fujifilm Corporation announced a new significant capital investment in the Danish location of FUJIFILM Diosynth Biotechnologies, the country's life science industry, totaling roughly 100 billion yen, or USD 928 million. The company hopes to increase its present contract research and production organisation for biologics and advanced therapeutic capabilities with this new capital investment from FUJIFILM Diosynth Biotechnologies. AbbVie Inc. and Genmab A/S, a Danish biotechnology company, entered into a cooperation agreement in June 2020 under which AbbVie would make an upfront payment of USD 4 billion to develop and market a number of Genmab's early-stage cancer medicines. Genmab will be able to expand its research and development pipeline with the aid of this milestone payment. Thus, the abovementioned factors are expected to increase the market growth.
However, the high tax rates on pharmaceutical products and price-cap agreements are expected to hinder the market growth.
Denmark Pharmaceutical Market Trends
This section covers the major market trends shaping the Denmark Pharmaceutical Market according to our research experts:
Prescription Drugs (Rx) accounted for the Significant Share of the Total Pharmaceutical Sales in Denmark
In Denmark, the prescriptions are not covered under public health insurance. However, the national scheme does reimburse the partial costs of some medications. Furthermore, in Denmark, the direct-to-consumer advertising of prescription drugs is permitted under strict legislation. This is having a positive impact on the market as most pharmacists and end-users will be well aware of new or present medications available for the treatment of diseases. Prescription drug sales have increased as compared to previous years owing to the rising chronic disease.
According to Globocan 2020, Denmark has an estimated 42,891 incidents of cancer. Colorectal cancer is the most common type of cancer, followed by breast, lung, prostate, and skin melanoma. Major competitors in the prescription drug market are making substantial advancements for the unmet requirement that exists in the market space as a result of the rising prevalence of chronic diseases in this area. For instance, a major player in this market, Novo Nordisk, is conducting a clinical trial comparing once-weekly semaglutide 2.0 mg to once-weekly semaglutide 1.0 mg. In November 2020, the company announced that the SUSTAIN FORTE trial, a 40-week, phase 3b, efficacy and safety trial with once-weekly semaglutide 2.0, had demonstrated a statistically significant and superior reduction in HbA1c at week 40. The business wants to market the medicine and get additional regulatory approval. Similarly, the world's largest diabetic manufacturer, Novo Nordisk, purchased Corvidia Therapeutics from AstraZeneca in June 2020 for an initial USD 725 million as it aims to diversify into cardiovascular disease medicines in the Danish market. Thus, the abovementioned factors are expected to increase the market growth.
Denmark Pharmaceutical Industry Overview
The pharmaceutical industry is competitive and consists of several major players in Denmark having a major focus on research and development. Some of the major pharmaceutical companies in the country are Novo Nordisk A/S, H. Lundbeck A/S, Leo Pharma A/S, Orifarm Group A/S, ALK-Abelló A/S, Xellia ApS, Takeda Pharma A/S, Sandoz A/S, Ferring Pharmaceuticals A/S, and FUJIFILM Diosynth Biotechnologies
Denmark Pharmaceutical Market Leaders
-
Novo Nordisk A/S
-
Leo Pharma A/S
-
H. Lundbeck A/S
-
Orifarm Group A/S
-
ALK-Abelló Nordic A / S
*Disclaimer: Major Players sorted in no particular order
Denmark Pharmaceutical Market News
- In July 2022, Bavarian Nordic, the Danish company is expanding its production capacity to 10 million doses of the monkeypox vaccine.
- In June 2022, Novo Nordisk A/S, a top global healthcare organization, and Echosens, a high-tech business providing liver diagnostic tools, entered into a partnership to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise patient awareness of the condition.
Denmark Pharmaceutical Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions & Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
-
4.1 Market Overview
- 4.1.1 Healthcare Expenditure (Govt. Vs Private)
- 4.1.2 Pharmaceutical Imports and Exports
- 4.1.3 Epidemeology Data For key Diseases
- 4.1.4 Regulatory Landscape/Regulatory Bodies
- 4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)
- 4.1.6 Pipeline Analysis
- 4.1.6.1 By Phase
- 4.1.6.2 By Sponsor
- 4.1.6.3 By Disease
- 4.1.7 Statiscal Overview
- 4.1.7.1 Number of Hospitals
- 4.1.7.2 Employment in the Pharmaceutical Sector
- 4.1.7.3 R&D Expenditure
- 4.1.8 Ease of Doing Business
-
4.2 Market Drivers
- 4.2.1 Collaboration between Private and Public Sector
- 4.2.2 Rising Funding for Research and Development
-
4.3 Market Restraints
- 4.3.1 High Tax Rates on Pharmaceutical Products
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By ATC/Therapeutic Class
- 5.1.1 Alimentary Tract and Metabolism
- 5.1.2 Blood and Blood Forming Organs
- 5.1.3 Cardiovascular System
- 5.1.4 Dermatological Drugs
- 5.1.5 Genitourinary System and Reproductive Hormones
- 5.1.6 Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin
- 5.1.7 Antiinfectives for Systemic Use
- 5.1.8 Antineoplastic and Immunomodulating Agents
- 5.1.9 Musculoskeletal System
- 5.1.10 Nervous System
- 5.1.11 Antiparasitic Products, Insecticides and Repellents
- 5.1.12 Respiratory System
- 5.1.13 Sensory Organs
- 5.1.14 Various ATC Structures
-
5.2 By Sector
- 5.2.1 Primary Sector
- 5.2.2 Hospital Sector
-
5.3 By Prescription Type
- 5.3.1 Prescription Drugs (Rx)
- 5.3.2 OTC Drugs
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Novo Nordisk A/S
- 6.1.2 H. Lundbeck A/S
- 6.1.3 Leo Pharma A/S
- 6.1.4 Orifarm Group A/S
- 6.1.5 ALK-Abell A/S
- 6.1.6 Xellia ApS
- 6.1.7 Takeda Pharma A/S
- 6.1.8 Sandoz A/S
- 6.1.9 Ferring Pharmaceuticals A/S
- 6.1.10 FUJIFILM Diosynth Biotechnologies
- *List Not Exhaustive
7. COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDenmark Pharmaceutical Industry Segmentation
As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without a doctor's prescription. The report also covers an in-depth analysis of qualitative and quantitative data. The Denmark Pharmaceutical Market is segmented by ATC/Therapeutic Class ( Alimentary Tract and Metabolism, Blood and Blood Forming Organs, Cardiovascular System, Dermatologicals Drugs, Genitourinary System and Reproductive Hormones, Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin, Anti-infectives for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Antiparasitic Products, Insecticides, and Repellents, Respiratory System, Sensory Organs, and Various ATC Structures), Sector (Primary Sector, and Hospital Sector), and Prescription Type (Prescription Drugs and OTC). The report offers the value (in USD million) for all the above segments.
| By ATC/Therapeutic Class | Alimentary Tract and Metabolism |
| Blood and Blood Forming Organs | |
| Cardiovascular System | |
| Dermatological Drugs | |
| Genitourinary System and Reproductive Hormones | |
| Systemic Hormonal Preparations, excluding Reproductive Hormones and Insulin | |
| Antiinfectives for Systemic Use | |
| Antineoplastic and Immunomodulating Agents | |
| Musculoskeletal System | |
| Nervous System | |
| Antiparasitic Products, Insecticides and Repellents | |
| Respiratory System | |
| Sensory Organs | |
| Various ATC Structures | |
| By Sector | Primary Sector |
| Hospital Sector | |
| By Prescription Type | Prescription Drugs (Rx) |
| OTC Drugs |
Denmark Pharmaceutical Market Research FAQs
What is the current Denmark Pharmaceutical Market size?
The Denmark Pharmaceutical Market is projected to register a CAGR of 3.40% during the forecast period (2024-2029)
Who are the key players in Denmark Pharmaceutical Market?
Novo Nordisk A/S, Leo Pharma A/S, H. Lundbeck A/S, Orifarm Group A/S and ALK-Abelló Nordic A / S are the major companies operating in the Denmark Pharmaceutical Market.
What years does this Denmark Pharmaceutical Market cover?
The report covers the Denmark Pharmaceutical Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Denmark Pharmaceutical Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Denmark Pharmaceutical Industry Report
The Denmark Pharmaceutical Companies report offers an extensive market overview, focusing on market trends and industry trends. The market is segmented by ATC/Therapeutic Class, including various sectors such as the cardiovascular system, dermatological drugs, and the nervous system. The report also details the market segmentation by sector, covering both the primary and hospital sectors, as well as by prescription type, including both prescription drugs and OTC.
This industry report provides an in-depth industry analysis and market analysis, highlighting the market size and industry size in USD million. The report includes a comprehensive market forecast and market outlook, projecting growth rate and industry growth. It also covers industry information, industry statistics, and industry trends, offering valuable insights into the market value and market data.
Furthermore, the report features industry reports and research companies, providing a detailed industry profile and sector analysis. The report pdf is available for download, serving as a valuable resource for understanding the market structure and market review. The report also identifies market leaders and offers a market overview, making it an essential tool for market research and industry research.
In summary, this report example provides a thorough analysis of the Denmark Pharmaceutical market, including industry sales and market growth. It offers detailed market predictions and market outlook, making it a crucial resource for understanding the industry worth and market trends. The report is a valuable asset for anyone looking to gain insights into the pharmaceutical industry in Denmark.
